Flawless or fallible? A review of the applicability of the European union's cosmetics directive in relation to nano-cosmetics

Studies in Ethics, Law, and Technology

Volumn 2, Issue 3, 2009, Pages

  Bowman, Diana M ^a   Van Calster, Geert ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cosmetics; European Union; Nanotechnologies; Regulation

Indexed keywords

EID: 68249102163     PISSN: None     EISSN: 19416008     Source Type: Journal    
DOI: 10.2202/1941-6008.1056     Document Type: Article

References (76)

1. Advanced Nanotechnology Limited (2006a), World's Finest Nano Materials -Alusions, Perth: Advanced Nano. Available at: http://www. advancednanotechnology.com/alusion.php
2. Advanced Nanotechnology Limited (2006b), Products - Alumina, Perth: Advanced Nano. Available at: http://www.advancednanotechnology.com/alumina.php
3. Alvarez-Roman, R. A. Naik, and Y.N. Kalia, et al. (2001), 'Biodegradable polymer nanocapsules containing a sunscreen agent: preparation and photoprotection', European Journal of Pharmaceutics and Biopharmaceutics, 52(2), 191-195.
4. Alvarez-Roman, R. A. Naik, and Y.N. Kalia, et al. (2005), 'Skin penetration and distribution of polymeric nanoparticles', Journal of Controlled Release, 99(1), 53-62.
5. Aitken, R., K. Creely and L. Tran (2004), Nanoparticles: An occupational hygiene review, Edinburgh: Institute of Occupational Medicine for the Health and Safety Executive
6. Barratt, G.M. (2000), 'Therapeutic applications of colloidal drug carriers', Pharmaceutical Science & Technology Today, 3(5), 163-171.
7. Bouchemal, K., S. Briancon, E. Perrier, et al. (2004), 'Synthesis and characterization of polyurethane and poly(ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification', International Journal of Pharmaceutics, 269(1), 89-100.
8. Bowman, D.M. and G.A. Hodge (2007), 'A Small Matter of Regulation: An International Review of Nanotechnology Regulation', Columbia Science and Technology Law Review, 8, 1-35.
9. Bowman, D.M. and G. van Calster (2007), 'Reflecting on REACH: Global Implications of the European Union's Chemicals Regulation', Nanotechnology Law & Business, 4(3), 375-384.
10. Chaudhry, Q., J. Blackburn, P. Floyd et al. (2006), Final Report: A scoping study to identify gaps in environmental regulation for the products and applications of nanotechnologies, London: Defra.
11. Davies, C.J. (2006), Managing the Effects of Nanotechnology, Washington DC: Project on Emerging Technologies.
12. Cross, S.E., B. Innes, M.S. Roberts, et al. (2007), 'Human Skin Penetration of Sunscreen Nanoparticles: In-vitro Assessment of a Novel Micronized Zinc Oxide Formulation', Skin Pharmacology and Physiology, 20, 148-154.
13. Couvreur, P., G. Barratt, E. Fattal, et al. (2002), 'Nanocapsule technology: a review', Critical Reviews in Therapeutic Drug Carrier Systems, 19(2), 99-134.
14. Cunningham, J. (1996), 'Colour cosmetics', in D.F. Williams and W.H. Schmitt (eds), Chemistry and Technology of the Cosmetics and Toiletries Industry, Kluwer: Amsterdam, pp.149-182.
15. Environmental Working Group (2006), EWG Comments to FDA, Washington DC: EWB.
16. European Commission (2004), Comparative Study on Cosmetics Legislation in the EU and Other Principle Markets with Special Attention to so-called Borderline Products, Brussels: European Commission.
17. European Commission (2006a), REACH: Commission welcomes European Parliament vote on new EU chemicals legislation, 13 December (IP/06/1799), Brussels: European Commission.
18. European Commission (2006b), REACH in brief, Brussels: European Commission.
19. European Commission (2007a), Commission moves on with the simplification programme in the field of cosmetics, IP/07/37, Brussels: European Commission.
20. European Commission (2007b), Public Consultation Paper on the Simplification of Cosmetics Directive 76/768/EEC, Brussels: European Commission.
21. European Commission (2008a), Proposal for a Regulation of the European Parliament and of the Council on cosmetic products, COM (2008) 49, Brussels: European Commission.
22. European Commission (2008b), Regulatory Aspects of Nanomaterials: Summary of legislation in relation to health, safety and environmental aspects of nanomaterials, regulatory research needs and related measures {COM(2008) 366 final}, Brussels: European Commission.
23. Euromonitor International (2007), Global cosmetics and toiletries sales reach five year high in 2006. Available: http://www. marketresearchworld.net/index.php?option=content&task=vie w&id=1230&Itemid=
24. Faunce, T.A., K. Murray, H. Nasu, and D.M. Bowman (2008), 'Sunscreen Safety: The Precautionary Principle, The Australian Therapeutic Goods Administration and Nanoparticles in Sunscreens', NanoEthics, 2(3), 231-240.
25. Foldvari, M. (2001), 'Non-invasive administration of drugs through the skin: challenges in delivery system design', Pharmaceutical Science & Technology Today, 3(12), 417-425.
26. Food and Drug Administration (2006), Is It a Cosmetic, a Drug, or Both? (or Is It Soap?), Washington DC: FDA. Available at: http://vm.cfsan.fda.gov/∼dms/cos-218.html
27. Food and Drug Administration (2007), Nanotechnology - A Report of the U.S. Food and Drug Administration Nanotechnology Task Force, Washington DC: FDA.
28. Friends of the Earth (2006), Nanomaterials, sunscreens and cosmetics: Small ingredients, big risks, Melbourne: Friends of the Earth Australian and US.
29. Friends of the Earth (2007), Nanotechnology & Sunscreens, Melbourne: Friends of the Earth Australia, EU and US.
30. Guterres, S.S., M.P. Alves and A.R. Pohlmann (2007), 'Polymeric Nanoparticles, Nanospheres and Nanocapsules for Cutaneous Applications', Drug Target Insights, 2, 147-157.
31. Hadgraft, J. (2001), 'Skin, the final frontier', International Journal of Pharmaceutics, 224(1-2), 1-18.
32. Hoet, P., I. Bruske-Hohlfeld and O. Salata (2004), 'Review: Nanoparticles -known and unknown health effects', Journal of Nanobiotechnology, 2(12), 1-15.
33. Jenning, V., A. Gysler, M. Schafer-Korting, and H. Sven (2000), 'Vitamin A loaded solid lipid nanoparticles for topic use: occlusive properties and drug targeting to the upper skin', European Journal of Pharmaceutics and Biopharmaceutics, 49, 211-218.
34. Kafi, R., H. Kwak, W.E. Schumacher, et al. (2007), 'Improvement of Naturally Aged Skin With Vitamin A (Retinol)', Archives of Dermatology, 143(5), 606-612.
35. Kandlikar, M., G. Ramachandran, A.D. Maynard, et al. (2007), 'Health risk assessment for nanoparticles: A case for using expert judgement', Journal of Nanoparticle Research, 9, 137-156.
36. Kaur, I.P. and R. Agrawal (2007), 'Nanotechnology: A New Paradigm in Cosmeceuticals', Recent Patents on Drug Delivery & Formulation, 1(2), 171-182.
37. Kimbrell, G.A. (2006), 'Nanomaterial Consumer Products and FDA Regulation: Regulatory Challenges and Necessary Amendments', Nanotechnology Law & Business, 3(3), 329-338.
38. Lasic, D.D. (1997), 'Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo', Journal of Controlled Release, 48(2-3), 203-222.
39. Lasic, D.D. (1998), 'Novel applications of liposomes', Trends in Biotechnology, 16(7), 307-321.
40. Lupo, M. (2001), 'Antioxidants and vitamins in cosmetics', Clinics in Dermatology, 19(4), 467-473.
41. Maynard, A.D. (2006), Nanotechnology: A Research Strategy for Addressing Risk, Washington DC: Project on Emerging Technologies.
42. Maynard, A.D. (2007), 'Nanotechnology: The Next Big Thing, or Much Ado about Nothing?', The Annuals of Occupational Hygiene, 51(1), 1-12.
43. Maynard, A.D., R. Aitken, T. Butz, et al. (2006), 'Safe handling of nanotechnology', Nature, 444, 267-269.
44. Maynard, A.D. and E.D. Kuempel (2005), 'Airborne nanostructured particles and occupational health', Journal of Nanoparticle Research, 7, 587-684.
45. Michaels, A.S., S.K. Chandrasekaran, and J.E. Shaw (1975), 'Drug permeation through human skin: Theory and invitro experimental measurement', AIChE Journal, 21, 985-996.
46. Morganti, P., E. Ruocco, R. Wolf, and V. Ruocco (2001), 'Percutaneous absorption and delivery systems', Clinics in Dermatology, 19(4), 489-501.
47. Moser, K., K. Kriwet, A. Naik, et al. (2001), 'Passive skin penetration enhancement and its quantification in vitro', European Journal of Pharmaceutics and Biopharmaceutics, 52(2), 103-112.
48. Mowad, C.M. (2001), 'A practical approach to patch testing for cosmetic allergens', Dermatologic Therapy, 14(3), 188-193.
49. Muller, R.H., K. Mader and S.H. Gohla (2000), 'Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art', European Journal of Pharmaceutics and Biopharmaceutics, 50, 161-177.
50. Nel, A., T. Xia, L. Madler, N. Li (2006), 'Toxic Potential of Materials at the Nanolevel', Science, 311, 622-627.
51. Nohynek, G.J., E.K. Dufour and M.S. Roberts (2008), 'Nanotechnology, Cosmetics and the Skin: Is there a Health Risk?', Skin Pharmacology and Applied Skin Physiology, 136-139.
52. Nohynek, G.J., J. Lademann, C. Ribaud, M.S. Roberts (2007), 'Grey Goo on the Skin? Nanotechnology, Cosmetic and Sunscreen Safety', Critical Reviews in Toxicology, 37(3), 251-277.
53. Oberdörster, G., V. Stone and K. Donaldson (2007), 'Toxicology of nanoparticles: A historical perspective', Nanotoxicology̧1(1), 2-25.
54. Oberdörster, G., A.D. Maynard, K. Donaldson, et al. (2005), 'Review: Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy', Particle and Fibre Toxicology, 2(8), 1-35.
55. Pauwels, M. and V. Rogiers (2004), 'Safety evaluation of cosmetics in the EU: Reality and challenges for the toxicologist', Toxicology Letters, 151(1), 7-17.
56. Poland, C.A., R. Duffin, I. Kinlock, et al. (2008), 'Carbon nanotubes introduced into the abdominal cavity of mice show asbestos like pathogenicity in a pilot study', Nature Nanotechnology, 3, 423-428.
57. SCP (2007), 'REACH - what you need to do and when you need to do it', SCP, July. Available at: http://www.cosmeticsbusiness.com/story.asp? storyCode=1590
58. Scientific Committee on Consumer Products (2005), Scientific Committee on Consumer Products - Request for a scientific opinion: Safety of Nanomaterials in Cosmetic Products, Brussels: SCCP. Available at: http://ec.europa.eu/health/ph-risk/committees/04-sccp/docs/sccp-nano-en .pdf
59. Scientific Committee on Consumer Products (2006), The SCCP's Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation, 6th Revision, Brussels: SCCP.
60. Scientific Committee on Consumer Products (2007), Opinion on Safety of Nanomaterials in Cosmetic Products, Brussels: SCCP. Available at: http://ec.europa.eu/health/ph-risk/committees/04-sccp/docs/sccp-o-123.p df
61. Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumer (2000), Opinion Concerning Titanium Dioxide, SCCNFP/0005/98, Brussels: SCCPNFP.
62. Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumer (2003), Opinion on Zinc Oxide, SCCNFP/0649/03, Brussels: SCCPNFP.
63. Scientific Committee on Emerging and Newly Identified Health Risks (2006), Modified opinion (after public consultation) on the appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious products of nanotechnologies, Brussels: SCENIHR.
64. Seaton, A. and K. Donaldson (2005), 'Nanoscience, nanotoxicology, and the need to think small', The Lancet, 365, 923-934. Sharma, A. and U.S. Sharma (1997), 'Liposomes in drug delivery: Progress and limitations', International Journal of Pharmaceutics, 154(2), 123-140.
65. Small Times (2006), 'The nanoscience behind beauty is serious business at L'Oreal', Small Times, 26 December. Available at: http://www.smalltimes. com/Articles/Article-Display.cfm?ARTICLE-ID= 268424&p=109
66. Soppimath, K.S., T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski (2001), 'Biodegradable polymeric nanoparticles as drug delivery devices', Journal of Controlled Release, 70(1-2), 1-20.
67. Swiss Re (2004), Nanotechnology: Small Matter, many unknowns, Geneva: Swiss Re.
68. Tadros, T.F. (1992), 'Future developments in cosmetic formulations', International Journal of Cosmetic Science, 14(3), 93-111.
69. Therapeutic Goods Administration (2006), A review of the scientific literature on the safety of nanoparticulate titanium dioxide and zinc oxide in sunscreens, Canberra: TGA.
70. Taylor, M. (2006), Regulating the Products of Nanotechnology: Does FDA Have the Tools It Needs?, Washington DC: Project on Emerging Nanotechnologies. Available at: http://nanotechproject.org/file-download/files/ PEN5-FDA.pdf;
71. Thomas, T., P. Aguar, H. Kawasaki, et al. (2006), 'Research Strategies for Safety Evaluation of Nanomaterials, Part VII: Evaluating Consumer Exposure to Nanoscale Materials', Toxicological Science, 91(1), 23-32.
72. Tsuji, J.S., A.D. Maynard, P.C. Howard, et al. (2006), 'Research Strategies for Safety Evaluation of Nanomaterials, Part IV: Risk Assessment of Nanoparticles', Toxicological Science, 89(1), 42-50.
73. Tuchinda, C., H.W. Lim, U. Osterwalder, and A. Rougier (2006), 'Novel Emerging Sunscreen Technologies', Dermatologic Clinics, 24(1), 105-117.
74. Verheugen (2006), Mr Verheugen on behalf of the EC, Parliamentary questions: Labelling and use of synthetic nanoparticles in sunscreens and cosmetics, E-2811/2006, 2006, Brussels: European Commission.
75. Weiner, N., L. Lieb, S. Niemiec, et al. (1994), 'Liposomes: a novel topical delivery system for pharmaceutical and cosmetic applications', Journal of Drug Targeting, 2(5), 405-410.
76. Which? (2008), Small Wonder? Nanotechnology and Cosmetics, London: Which?